PARTNERED

Thyroid hormone as a novel therapeutic agent in fibrotic lung diseases

• Idiopathic pulmonary fibrosis (IPF) is a lethal fibrotic lung disorder. The median survival of patients with IPF is 3.5-4 years from initial diagnosis, irrespective of treatment.
• Innovation:
  • Inhaled or aerosolized delivery of thyroid hormone to the lung – preliminary results demonstrate thyroid hormone resolves pulmonary fibrosis in animal models and increases survival.
• IP Status: PCT/US 15/317,276
• Lead Innovator: Naftali Kaminski, M.D.